NeuroSense Provides Business Update and Progress for the First Half of 2026
PR Newswire•25/09/2026•16:30 ET
0
NeuroSense Provides Business Update and Progress for the First Half of 2026 PR Newswire
CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ -- Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided a business update with corporate highlights to date and financial results for the first half of 2026.
Get started
Create a free account to read the full story and Whiz Insights.